MAS1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL15045765	1.00	1/20
SCHEMBL24637539	0.87	1/20
SCHEMBL18768098	0.87	1/20
SCHEMBL24637534	0.86	1/20
SCHEMBL24637550	0.85	1/20
SCHEMBL24019101	0.85	1/20
SCHEMBL24637561	0.84	1/20
SCHEMBL24637566	0.83	1/20
SCHEMBL24637565	0.81	1/20
SCHEMBL24637522	0.79	1/20
SCHEMBL24637535	0.76	1/20
SCHEMBL24637537	0.76	1/20
SCHEMBL24637533	0.74	1/20
SCHEMBL1334134	0.74	1/20
SCHEMBL3975878	0.73	1/20
SCHEMBL29701254	0.73	1/20
SCHEMBL19731367	0.73	1/20
SCHEMBL24637551	0.72	1/20
SCHEMBL24637568	0.69	1/20
SCHEMBL3908044	0.69	1/20

Clinical trials — most relevant to MAS1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Telmisartan for Treatment of COVID-19 Patients	PHASE4	COMPLETED
Bradykinin Receptor Antagonism During Cardiopulmonary Bypass	PHASE2/PHASE3	COMPLETED
Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial	PHASE2/PHASE3	UNKNOWN
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome	PHASE3	COMPLETED
NEO100 and High-Grade Meningioma	PHASE2	RECRUITING
Angiotensin 1-7 as a Therapy in the Treatment of COVID-19	PHASE2	UNKNOWN
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma	PHASE1/PHASE2	SUSPENDED
A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma	PHASE1/PHASE2	COMPLETED
Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1	PHASE2	COMPLETED
Antioxidant Therapy With N-acetylcysteine for Learning and Motor Behavior in Children With Neurofibromatosis Type 1	PHASE2	COMPLETED
BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors	PHASE2	WITHDRAWN
Combination of Recombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP and Isotretinoin Could be Promising Treatment for COVID-19 Infection- and Its Inflammatory Complications	PHASE1	UNKNOWN
Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy	PHASE1	WITHDRAWN
PAS-004 in Patients With Advanced Solid Tumors	PHASE1	RECRUITING
Expression and Function of the Renin-Angiotensin System in the Esophagus	EARLY_PHASE1	COMPLETED
RAS and Coagulopathy in COVID19	EARLY_PHASE1	COMPLETED
The Role of Maspin in Colorectal Carcinoma, an Immunohistochemical Study	nan	NOT_YET_RECRUITING
Clinical Study Evaluating the Effect of Losartan	nan	RECRUITING
Influence of Genetic Polymorphisms on Ventricular Structure and Function in Patients With Single Ventricle Anatomy	nan	COMPLETED
Renal Transplant Injury and the Renin-Angiotensin System in Kids (RETASK)	nan	COMPLETED
The Effect of RAAS Blockers on ACE2 Levels	nan	COMPLETED
Study of PNPLA3 Genetic Polymorphisms in Patients With Non-Alcoholic Fatty Liver Disease in an Ultramarine Population (AdipoDROMExpo)	nan	RECRUITING
Genetic Architecture of Plasma T-PA and PAI-1	nan	COMPLETED
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies	nan	RECRUITING
Genetics of Hypertension in Blacks	nan	COMPLETED
Counter-Regulatory Hormonal and Stress Systems in Patients With COVID-19	nan	COMPLETED
Long Term Prediction of MASH-related HCC Risk by Proteomics	nan	NOT_YET_RECRUITING
Changes After Angiotensin Converting Enzyme (ACE) Inhibitor Replacement by Angiotensin II Receptor Type I (AT1) Blocker	nan	UNKNOWN
Hematological Anomalies in Children With Rasopathy	nan	RECRUITING
Semen Analysis Changes in Covid-19 Positivepatients	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a MAS1 binder may also engage these)

Protein	Name	Similarity
P12526	—	1.000	P12526 →
P30554	—	0.999	P30554 →
Q7TN38	—	0.998	Q7TN38 →
Q99MT8	—	0.996	Q99MT8 →
P23749	—	0.983	P23749 →
Q91ZC4	—	0.981	Q91ZC4 →
Q91ZB8	—	0.980	Q91ZB8 →
Q8VCJ6	—	0.980	Q8VCJ6 →
Q7TN44	—	0.979	Q7TN44 →
P35410	—	0.975	P35410 →
Q3KNA1	—	0.975	Q3KNA1 →
Q91ZB9	—	0.974	Q91ZB9 →
Q91WW2	—	0.973	Q91WW2 →
Q3UG61	—	0.973	Q3UG61 →
Q646C8	—	0.973	Q646C8 →
Q96AM1	—	0.973	Q96AM1 →
Q91ZC5	—	0.972	Q91ZC5 →
Q7TN51	—	0.972	Q7TN51 →
Q67ET2	—	0.972	Q67ET2 →
TAS2R39	Taste receptor type 2 member 39	0.971	landscape →
Q646F0	—	0.970	Q646F0 →
Q645Y7	—	0.970	Q645Y7 →
Q9JKT2	—	0.970	Q9JKT2 →
Q9JKU1	—	0.969	Q9JKU1 →
Q91ZC1	—	0.969	Q91ZC1 →
Q645Y8	—	0.969	Q645Y8 →
Q7TQA6	—	0.969	Q7TQA6 →
Q646D1	—	0.968	Q646D1 →
Q7TN41	—	0.968	Q7TN41 →
Q646D3	—	0.968	Q646D3 →